JP2021506982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506982A5 JP2021506982A5 JP2020554358A JP2020554358A JP2021506982A5 JP 2021506982 A5 JP2021506982 A5 JP 2021506982A5 JP 2020554358 A JP2020554358 A JP 2020554358A JP 2020554358 A JP2020554358 A JP 2020554358A JP 2021506982 A5 JP2021506982 A5 JP 2021506982A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cells
- use according
- reperfusion
- prc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 238000000034 method Methods 0.000 claims 8
- 208000028867 ischemia Diseases 0.000 claims 6
- 230000030833 cell death Effects 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 102000011727 Caspases Human genes 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 239000000162 organ preservation solution Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862710838P | 2018-03-01 | 2018-03-01 | |
| US62/710,838 | 2018-03-01 | ||
| PCT/CN2019/070444 WO2019165851A1 (en) | 2018-03-01 | 2019-01-04 | Novel aminothiol reduction of ischemia-reperfusion-induced cell death |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021506982A JP2021506982A (ja) | 2021-02-22 |
| JP2021506982A5 true JP2021506982A5 (https=) | 2021-04-01 |
| JP7121418B2 JP7121418B2 (ja) | 2022-08-18 |
Family
ID=67805623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554358A Active JP7121418B2 (ja) | 2018-03-01 | 2019-01-04 | 局所的な虚血－再灌流により誘発される細胞死の新型なアミノチオールによる減少 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11690813B2 (https=) |
| EP (2) | EP3758691A4 (https=) |
| JP (1) | JP7121418B2 (https=) |
| KR (1) | KR102490204B1 (https=) |
| CN (1) | CN111801095A (https=) |
| AU (1) | AU2019228134B2 (https=) |
| CA (1) | CA3092596C (https=) |
| WO (1) | WO2019165851A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL310131A (en) * | 2021-07-16 | 2024-03-01 | Obvia Pharmaceuticals Ltd | Prc-210 for use in the treatment of acute tissue injury |
| WO2024168231A1 (en) * | 2023-02-10 | 2024-08-15 | Obvia Pharmaceuticals, Ltd. | Aminothiols for the treatment of conditions characterized by protein misfolding or aggregation, mitochondrial dysfunction, or chronic inflammation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6031006A (en) | 1999-10-21 | 2000-02-29 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic nephropathy |
| US7314959B2 (en) | 2003-08-07 | 2008-01-01 | Wisconsin Alumni Research Foundation | Amino thiol compounds and compositions for use in conjunction with cancer therapy |
| JPWO2006011273A1 (ja) * | 2004-07-30 | 2008-07-31 | 独立行政法人科学技術振興機構 | 虚血後の再灌流性細胞死の抑制方法、および細胞死抑制剤 |
| EP3316877B1 (en) * | 2015-07-02 | 2019-10-30 | Horizon Orphan LLC | Ado-resistant cysteamine analogs and uses thereof |
-
2019
- 2019-01-04 KR KR1020207026024A patent/KR102490204B1/ko active Active
- 2019-01-04 US US16/629,851 patent/US11690813B2/en active Active
- 2019-01-04 JP JP2020554358A patent/JP7121418B2/ja active Active
- 2019-01-04 EP EP19760716.1A patent/EP3758691A4/en not_active Withdrawn
- 2019-01-04 AU AU2019228134A patent/AU2019228134B2/en active Active
- 2019-01-04 EP EP25151058.2A patent/EP4588472A1/en active Pending
- 2019-01-04 WO PCT/CN2019/070444 patent/WO2019165851A1/en not_active Ceased
- 2019-01-04 CN CN201980011285.XA patent/CN111801095A/zh active Pending
- 2019-01-04 CA CA3092596A patent/CA3092596C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reitz et al. | Heart and lung transplantation: autotransplantation and allotransplantation in primates with extended survival | |
| JP2019515908A5 (https=) | ||
| JP2022516099A5 (https=) | ||
| JP2023518777A5 (https=) | ||
| US5843996A (en) | Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution | |
| JP2012523432A5 (https=) | ||
| JP2021506982A5 (https=) | ||
| RU2468793C2 (ru) | Композиции на основе соединений 2-амино-1,3-пропандиола | |
| JP2004529928A5 (https=) | ||
| RU2002132189A (ru) | Препарат эсмолола | |
| RU2258700C1 (ru) | Четвертичное аммониевое производное лидокаина, обладающее противоаритмической активностью и способ его получения | |
| WO2001015525A1 (en) | Organ preservatives | |
| WO2008148474A2 (de) | Lösungen für die perfusion und konservierung von organen und geweben | |
| CA2907652C (en) | Compounds for the treatment of ischemia-reperfusion-related diseases | |
| JPH05361B2 (https=) | ||
| JP2016516830A (ja) | 酸素含有量が増加され、安定性が向上され、貯蔵寿命が長くなった臓器及び組織の保存溶液 | |
| Klein et al. | Intracoronary hyperosmotic mannitol during reperfusion does not affect infarct size in ischemic, reperfused porcine hearts | |
| TW201521577A (zh) | 用於增加器官及組織保存溶液之氧含量、安定性及保存壽命的含聚（０－２－羥乙基）澱粉調配物 | |
| CN101012240A (zh) | 磷酸肌酸精氨酸盐及其制备方法 | |
| JPH11511479A (ja) | １，２，４−ベンゾトリアジンオキシド製剤 | |
| WO1994026261A1 (en) | Treating body parts susceptible to ischemia using creatine analogs | |
| JP2665564B2 (ja) | 細胞防護剤 | |
| JP2003504404A (ja) | 抗虚血薬 | |
| JPS59176299A (ja) | 脈管形成因子阻害剤 | |
| JP2004231557A (ja) | エピネフリン含有抗腫瘍剤 |